^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Alkylating agent

    Related drugs:
    2d
    KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, Corregene Biotechnology Co., Ltd | Not yet recruiting --> Active, not recruiting | N=18 --> 8
    Enrollment closed • Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12
    |
    cyclophosphamide • fludarabine IV
    2d
    ALK-positive ALCL: first described adult case of synchronous CNS and systemic involvement at presentation: a case report and review of the literature. (PubMed, Br J Neurosurg)
    The patient was treated with a modified MARIETTA protocol (without rituximab) and consolidated with a carmustine-based autologous stem cell transplant. shows complete metabolic response on PET-CT and MRI brain. This case presents the first successful treatment of a synchronous presentation of CNS and systemic ALK-positive ALCL, and the importance of a multidisciplinary approach for diagnosis.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • NPM1 (Nucleophosmin 1) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • ALK fusion • ALK translocation
    |
    Rituxan (rituximab) • carmustine
    3d
    Safety and efficacy of hyperthermic intraperitoneal chemotherapy of lobaplatin after cytoreductive surgery for appendiceal mucinous neoplasm with PCI>=20: a prospective, single-arm, single-center clinical trial (ChiCTR2500113397)
    P=N/A, N=47, Not yet recruiting, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
    New trial
    |
    lobaplatin (D19466)
    3d
    A clinical study on the use of thiotepa in combination with semustine and cytarabine for conditioning of autologous hematopoietic stem cell transplantation in primary central nervous system lymphoma (ChiCTR2500111944)
    P=N/A, N=22, Not yet recruiting, Henan Provincial People's Hospital; Henan Provincial People's Hospita,medical
    New trial
    |
    CD34 (CD34 molecule)
    |
    cytarabine • thiotepa
    3d
    Efficacy and Safety of Iparomlimab and Tuvonralimab Combined with Albumin-bound Paclitaxel and Lobaplatin as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer：A Prospective, Multicenter, Single-Arm Study (ChiCTR2500114072)
    P4, N=67, Not yet recruiting, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 amplification • HER-2 negative • ER negative
    |
    albumin-bound paclitaxel • lobaplatin (D19466) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    A phase II clinical study evaluating the efficacy and safety of Decitabine combined with Melphalan in newly diagnosed MDS-IB (ChiCTR2500115218)
    P2, N=28, Not yet recruiting, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    decitabine • melphalan
    3d
    Phase IIb Trial of AST-3424 in Patients with AKR1C3-High Expression Advanced Hepatocellular Carcinoma Previously Treated with Immune Checkpoint Inhibitor-Based Therapy (ChiCTR2500114071)
    P2, N=75, Not yet recruiting, Nanjing Tianyi Mountain Hospital; Nanjing Tianyi Mountain Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • AKR1C3 (Aldo-Keto Reductase Family 1 Member C3)
    |
    Stivarga (regorafenib) • OBI-3424
    3d
    DEMEL-1: A single-center, single-arm, phase II clinical study evaluating the efficacy and safety of Decitabine combined with low-dose Melphalan in patients with high-risk refractory myelodysplastic syndrome (ChiCTR2500115432)
    P2, N=20, Not yet recruiting, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    decitabine • melphalan
    4d
    Yangxuebushen Decoction prevents cyclophosphamide-induced hair loss by inhibiting hair follicle apoptosis. (PubMed, Cutan Ocul Toxicol)
    YXBSD effectively alleviated CYP-induced alopecia by inhibiting apoptosis in hair follicle cells while concurrently reducing inflammation and oxidative stress, thereby promoting the recovery of hair follicle structure and function. These findings suggest that YXBSD has potential as an adjuvant intervention for chemotherapy-induced alopecia.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    |
    cyclophosphamide
    4d
    Successful Treatment of Peripheral T-cell Lymphoma Not Otherwise Specified in Bilateral Subconjunctiva: A Case Report. (PubMed, Cureus)
    The patient achieved complete remission with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy and remains disease-free after three years. To our knowledge, this represents the first reported case of primary bilateral subconjunctival PTCL-NOS successfully managed with systemic chemotherapy, highlighting the importance of comprehensive evaluation and aggressive treatment in this unusual presentation.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine
    4d
    A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity (clinicaltrials.gov)
    P2, N=51, Completed, Sidney Kimmel Cancer Center at Thomas Jefferson University | Active, not recruiting --> Completed
    Trial completion
    |
    cyclophosphamide
    5d
    SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells (clinicaltrials.gov)
    P1, N=24, Recruiting, General Oncology, Inc. | N=10 --> 24 | Trial completion date: Aug 2027 --> Dec 2028 | Trial primary completion date: Aug 2026 --> Dec 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative • PALB2 mutation
    |
    carmustine • melphalan • Mustargen (mechlorethamine)